MDXGNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
MIMEDX GROUP, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$4.38−0.05 (-1.13%)
Close on Oct 19, 2026
- Market cap
- $647.35M
- P/E (TTM)
- 109.5
- Dividend yield
- –
Mimedx statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | Mimedx | Industry median |
|---|---|---|
| Market Cap | $638.43M | $230.55M |
| Enterprise Value | $519.80M | $202.97M |
| PE Ratio | 109.50 | 33.40 |
| PS Ratio | 1.80 | 3.11 |
| PB Ratio | 2.96 | 3.14 |
| P/TBV Ratio | 3.46 | 4.57 |
| P/OCF Ratio | 13.83 | 22.35 |
Enterprise value
| Measure | Mimedx | Industry median |
|---|---|---|
| EV / Sales | 1.46 | 2.92 |
| EV / EBITDA | 59.39 | 19.86 |
| EV / EBIT | 59.39 | 24.88 |
Income (trailing twelve months)
| Measure | Mimedx | Industry median |
|---|---|---|
| Revenue | $355.17M | $102.39M |
| Gross Profit | $280.05M | $60.36M |
| Operating Income | $8.75M | -$4.31M |
| Pretax Income | $11.53M | -$2.26M |
| Net Income | $6.24M | -$6.57M |
| EBITDA | $8.75M | -$1.98M |
| EPS (Diluted) | $0.04 | -$0.07 |
Margins
| Measure | Mimedx | Industry median |
|---|---|---|
| Gross Margin | 78.8% | 55.1% |
| Operating Margin | 2.46% | -6.04% |
| Pretax Margin | 3.25% | -4.11% |
| Profit Margin | 1.76% | -10.5% |
| EBITDA Margin | 2.46% | -2.67% |
Returns
| Measure | Mimedx | Industry median |
|---|---|---|
| Return on Equity (ROE) | 2.88% | -19.2% |
| Return on Assets (ROA) | 2.18% | -13.3% |
| Return on Invested Capital (ROIC) | 4.43% | -4.11% |
| Return on Capital Employed (ROCE) | 3.61% | -9.07% |
Growth
| Measure | Mimedx | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -2.36% | 8.85% |
| Net Income Growth (YoY) | -80.6% | 10.6% |
| EPS Growth (YoY) | -81.0% | 10.6% |
| Revenue Growth (3Y CAGR) | 16.1% | 7.08% |
| Revenue Growth (5Y CAGR) | 11.0% | 11.8% |
Balance sheet
| Measure | Mimedx | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $135.84M | $37.33M |
| Total Debt | $17.21M | $72.66M |
| Net Cash (Debt) | $118.63M | $3.92M |
| Net Cash Per Share | $0.81 | $0.28 |
| Equity (Book Value) | $216.00M | $57.36M |
| Book Value Per Share | $1.48 | $2.81 |
| Tangible Book Value | $184.48M | $10.71M |
| Working Capital | $166.87M | $54.64M |
Financial position
| Measure | Mimedx | Industry median |
|---|---|---|
| Current Ratio | 5.33 | 2.50 |
| Quick Ratio | 4.60 | 1.54 |
| Debt / Equity | 0.08 | 0.38 |
| Debt / EBITDA | 1.97 | 2.31 |
| Net Debt / EBITDA | -13.55 | 1.53 |
Cash flow (trailing twelve months)
| Measure | Mimedx | Industry median |
|---|---|---|
| Operating Cash Flow | $46.15M | -$653.46K |
Efficiency
| Measure | Mimedx | Industry median |
|---|---|---|
| Asset Turnover | 1.24 | 0.59 |
| Inventory Turnover | 3.28 | 2.21 |
| Revenue Per Employee | $439.57K | $322.57K |
| Profits Per Employee | $7.72K | -$51.88K |
| Employee Count | 808 | 185 |
Dividends and yields
| Measure | Mimedx | Industry median |
|---|---|---|
| Earnings Yield | 0.98% | -6.91% |
Shares
| Measure | Mimedx | Industry median |
|---|---|---|
| Shares Outstanding | 145,760,000 | 44,856,700 |
| Shares Change (YoY) | -0.09% | 3.35% |
| Shares Change (QoQ) | -2.15% | 0.27% |
| Float | 141,546,000 | 37,097,900 |
| Shares Held by Insiders | 2.89% | 10.6% |
| Shares Held by Institutions | 80.0% | 63.5% |
Taxes
| Measure | Mimedx | Industry median |
|---|---|---|
| Income Tax | $5.29M | $1.52M |
| Effective Tax Rate | 45.9% | 18.6% |
Scores
| Measure | Mimedx | Industry median |
|---|---|---|
| Graham Number | $1.15 | $34.37 |
| Graham Upside | -73.6% | -57.7% |
| Altman Z-Score | 7.63 | 1.95 |
| Piotroski F-Score | 6 | 5 |
| Beneish M-Score | -2.68 | -2.64 |
Calculated by StockData from Mimedx's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.